



For Immediate Release

October 21, 2019

**REVOCATION OF CEASE TRADE ORDERS GRANTED
AND COMPANY ANNOUNCES DATE FOR ANNUAL AND SPECIAL MEETING**

Vancouver, B.C., October 21, 2019 – Endocan Solutions Inc. (the “Company” or “Endocan”) reports that the cease trade order issued by the British Columbia Securities Commission (BCSC) on May 3, 2016 and the cease trade order issued by the Ontario Securities Commission (OSC) on May 6, 2016 have been revoked.

The Company has set December 20, 2019 for its Annual General & Special Meeting of Shareholders.

The Company is currently pursuing a business acquisition and is considering a financing to support the acquisition.

About Endocan Solutions Inc.

Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the Canadian Securities Exchange (the “CSE”) on December 6, 2016, was subsequently put under new management, and has since undergone a name change and share consolidation. The Company has recently brought required filings up to date under National Instrument 51-102, which includes audited annual financial statements with accompanying MD&A and Officer Certificates for the years ended October 31, 2015, 2016, 2017 and 2018. The immediate objective is to recapitalize the Company and management intends to seek and secure a suitable business acquisition and requalify the Company to meet the listing requirements of the CSE.

ON BEHALF OF ENDOCAN SOLUTIONS INC.

(signed) “Bruce Clark”
Chief Executive Officer

For further information, please contact:

Bruce Clark

Telephone: +1.604.401.8100

endocansolutions@gmail.com

Cautionary Statements

This press release contains forward-looking information based on current expectations. Statements about the Company's expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Endocan Solutions assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbour.